Menopausale Hormontherapie 15 Jahre post WHI: Sicherheit geht vor

Originalien
  • 6 Downloads

Zusammenfassung

Die Publikation des Östrogen-Gestagen-Arms der WHI-Studie 2002 (WHI: Women’s Health Initiative) war von Fehlinterpretationen der Studienresultate gekennzeichnet. Anhand der Post-WHI-Literatur zur menopausalen Hormontherapie (MHT) werden die tatsächlichen und vermeintlichen Risiken für Brustkrebs, venöse Thromboembolien, Schlaganfall und koronare Herzkrankheit analysiert. Die sich daraus ableitenden Sicherheitsmaßnahmen, wie der Beginn der MHT in der Peri- oder frühen Postmenopause („window of opportunity“), die transdermale Östrogenadministration und die Auswahl eines neutralen Progestogens, können das Risiko minimieren und den Nutzen bei therapeutischen und präventiven Indikationen maximieren.

Schlüsselwörter

Menopausale Hormontherapie WHI-Studie Sicherheitsdaten „Window of opportunity“ Transdermale Östrogenadministration Progestogene 

Menopause hormone therapy 15 years after the WHI: Safety first

Abstract

The publication of the estrogen-progestin arm of the WHI Study 2002 (WHI, Women’s Health Initiative) was characterized by misinterpretations of its results. Actual and putative risks of breast cancer, venous thromboembolism, stroke, and coronary heart disease are revised by means of the post-WHI literature on menopause hormone therapy (MHT). Conclusive safety measures as to initiate MHT in perimenopausal or early postmenopausal years (window of opportunity), transdermal estrogen administration and the choice of neutral progestogens may minimize the risks and maximize the benefits for therapeutic and preventive indications.

Keywords

Menopause Hormone Therapy WHI Study Safety data Window of opportunity Transdermal estrogen administration Progestogens 

Notes

Einhaltung ethischer Richtlinien

Interessenkonflikt

E. Boschitsch gibt an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Literatur

  1. 1.
    Langer RD (2017) The evidence base for Hormone Replacement Therapy (HRT): what can we believe? Climacteric 20:91–96CrossRefPubMedGoogle Scholar
  2. 2.
    Writing Group for the Women’s Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288:321–333CrossRefGoogle Scholar
  3. 3.
    The Women’s Health Initiative Study Group (1998) Design of the women’s health initiative clinical trial and observational study. Control Clin Trials 19:61–109CrossRefGoogle Scholar
  4. 4.
    Shapiro S (2003) Risks of estrogen plus progestin therapy: a sensitivity analysis of findings in the Women’s Health Initiative randomized controlled trial. Climacteric 6(4):302–310. (discussion 310–313)CrossRefPubMedGoogle Scholar
  5. 5.
    National Institutes of Health (2002) NHLBI stops trial of estrogen plus progestin due to increased breast cancer risk, lack of overall benefit. Press release. http://www.nhlbi.nih.gov/whi/pr_02-7-9.pdf. Zugegriffen: 29. Okt. 2016Google Scholar
  6. 6.
    Anderson GL, Chlebowski RT, Rossouw JE et al (2006) Prior hormone therapy and breast cancer risk in the Women’s Health Initiative randomized trial of estrogen plus progestin. Maturitas 55:103–115CrossRefPubMedGoogle Scholar
  7. 7.
    Baber RJ, Panay N, Fenton A, Writing Group (2016) IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric 19(2):109–150CrossRefPubMedGoogle Scholar
  8. 8.
    Women’s Health Initiative Steering Committee, Anderson GL, Limacher M, Assaf AR et al (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the women’s health initiative randomized controlled trial. JAMA 291(14):1701–1712CrossRefGoogle Scholar
  9. 9.
    North American Menopause Society (2017) Menopause glossary. https://www.menopause.org/for-women/menopause-glossary. Zugegriffen: 1. Okt. 2017Google Scholar
  10. 10.
    Fournier A, Berrino F, Clavell-Chapelon F (2008) Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 107:103–111CrossRefPubMedGoogle Scholar
  11. 11.
    Cordina-Duverger E, Truong T, Anger A et al (2013) Risk of breast cancer by type of menopausal hormone therapy: a case-control study among post-menopausal women in France. PLOS ONE 8:e78016CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Lyytinen H, Pukkala E, Ylikorkala O (2009) Breast cancer risk in postmenopausal women using estradiol—progestogen therapy. Obstet Gynecol 113:65–73CrossRefPubMedGoogle Scholar
  13. 13.
    Renoux C, Dell’Aniello S, Suissa S (2010) Hormone replacement therapy and the risk of venous thromboembolism: a population based study. J Thromb Haemost 8:979–986PubMedGoogle Scholar
  14. 14.
    Canonico M, Fournier A, Carcaillon L et al (2010) Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study. Arterioscler Thromb Vasc Biol 30:340–345CrossRefPubMedGoogle Scholar
  15. 15.
    Canonico M, Oger E, Conard J et al (2006) Obesity and risk of venous thromboembolism among postmenopausal women: differential impact of hormone therapy by route of estrogen administration. The ESTHER Study. J Thromb Haemost 4:1259–1265CrossRefPubMedGoogle Scholar
  16. 16.
    Canonico M, Alhenc-Gelas M, Plu-Bureau G, Olié V, Scarabin PY (2010) Activated protein C resistance among postmenopausal women using transdermal estrogens: importance of progestogen. Menopause 17(6):1122–1127CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Olié V, Canonico M, Scarabin PY (2010) Risk of venous thrombosis with oral versus transdermal estrogen therapy among postmenopausal women. Curr Opin Hematol 17(5):457–463CrossRefPubMedGoogle Scholar
  18. 18.
    Henderson VW, Lobo RA (2012) Hormone therapy and the risk of stroke: perspectives 10 years after the Women’s Health Initiative trials. Climacteric 15:229–234CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Manson JE, Chlebowski RT, Stefanick ML et al (2013) Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA 310:1353–1368CrossRefPubMedGoogle Scholar
  20. 20.
    Boardman HM, Hartley L, Eisinga A et al (2015) Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev.  https://doi.org/10.1002/14651858.CD002229.pub4 PubMedGoogle Scholar
  21. 21.
    Renoux C, Dell’aniello S, Garbe E et al (2010) Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study. BMJ 340:c2519CrossRefPubMedGoogle Scholar
  22. 22.
    Canonico M, Carcaillon L, Plu-Bureau G, Oger E, Singh-Manoux A, Tubert-Bitter P, Elbaz A, Scarabin PY (2016) Postmenopausal hormone therapy and risk of stroke: impact of the route of estrogen administration and type of progestogen. Stroke 47(7):1734–1741CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE, Hennekens CH (1991) Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses’ health study. N Engl J Med 325(11):756–762CrossRefPubMedGoogle Scholar
  24. 24.
    Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E (1998) Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 280(7):605–613CrossRefPubMedGoogle Scholar
  25. 25.
    Clarkson TB (1994) Estrogens, progestins, and coronary heart disease in cynomolgus monkeys. Fertil Steril 62(6 Suppl 2):147S–151SPubMedGoogle Scholar
  26. 26.
    Adams MR, Williams JK, Clarkson TB, Jayo MJ (1991) Effects of oestrogens and progestogens on coronary atherosclerosis and osteoporosis of monkeys. Baillieres Clin Obstet Gynaecol 5(4):915–934CrossRefPubMedGoogle Scholar
  27. 27.
    Hu P, Greendale GA, Palla SL et al (2006) The effects of hormone therapy on the markers of inflammation and endothelial function and plasma matrix metalloproteinase-9 level in postmenopausal women: the Postmenopausal Estrogen Progestin Intervention (PEPI) trial. Atherosclerosis 185:347–352CrossRefPubMedGoogle Scholar
  28. 28.
    Galis ZS, Sukhova GK, Lark MV, Libby P (1994) Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 94:2493–2503CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    ELITE Research Group, Hodis HN, Mack WJ, Henderson VW et al (2016) Vascular effects of early versus late postmenopausal treatment with estradiol. N Engl J Med 374(13):1221–1231CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Austria, ein Teil von Springer Nature 2017

Authors and Affiliations

  1. 1.Ambulatorium KlimaxWienÖsterreich

Personalised recommendations